Determining proton pump inhibitor prescription dispensing patterns and adherence to STOPP criteria for Nova Scotia Seniors Pharmacare Program beneficiaries
Jillian H. Carter\textsuperscript{1,2}, Ingrid S. Sketris\textsuperscript{1,3}, Hala Tamim\textsuperscript{4}, Adrian R. Levy\textsuperscript{1} and Joanne M. Langley\textsuperscript{1,5,6}  
\textsuperscript{1}Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada  
\textsuperscript{2}Department of Emergency Medicine, Dalhousie University, Halifax, NS, Canada  
\textsuperscript{3}College of Pharmacy, Dalhousie University, Halifax, NS, Canada  
\textsuperscript{4}Faculty of Health, School of Kinesiology & Health Science, York University, Toronto, ON, Canada  
\textsuperscript{5}Canadian Center for Vaccinology, Dalhousie University, Halifax, NS, Canada  
\textsuperscript{6}Department of Pediatrics, Dalhousie University, Halifax, NS, Canada

Corresponding author: E-mail: ingrid.sketris@dal.ca

Submitted: 1 September 2018. Accepted: 24 December 2018. Published: 27 December 2019.

ABSTRACT

Background
Proton pump inhibitors (PPIs) are often prescribed potentially inappropriately. The screening tool of older person’s potentially inappropriate prescriptions (STOPP) for therapeutic dose PPIs has been adapted to examine PPI discontinuation, dose reduction, or switching to Histamine-2 Receptor Antagonist (H2RA) after 60 days.

Objectives
The objectives of the present study were to (1) describe the use of acid suppression therapy (PPIs and H2RAs) 60 and 90 days after a new PPI dispensing, (2) assess predictors of lack of adherence to adapted STOPP criteria for PPI use, and (3) assess PPI dispensing over time.

Methods
This was a retrospective cohort study of beneficiaries of the Nova Scotia Seniors Pharmacare (NSSP) aged 66 years or older who were newly dispensed a PPI between January 1, 1997 and March 31, 2011. The main outcome measure was adherence to the adapted STOPP criteria, which was analyzed using logistic regression.
INTRODUCTION

Proton pump inhibitors (PPIs) are among the most widely prescribed medications globally, most often for acid-peptic disorders. PPIs are ranked fourth in terms of spending by Canadian publicly funded drug programs for older (>65 years) adults. In 2015, 34.8% of Nova Scotia adults aged 65 and over using public drug plans were dispensed at least one prescription for a PPI. Use of PPIs has been rising worldwide. According to the Canadian Institute for Health Information (CIHI), 14% of adults over 65 years of age who were beneficiaries of publicly funded drug programs in 2002 had at least one claim per year for PPI therapy. This increased to 25% per year in 2009, then 27% per year in 2012, and 32% per year in 2016.

The increase in PPI use may be due to policy, prescriber, or patient factors, including increased availability of both branded and generic PPIs. In Canada, each province’s drug insurance program has its own prescription drug formulary. When generic PPIs became available at decreased costs, some provinces reimbursed more types of PPIs or more indications for PPI therapy. This may have allowed more patients to access PPIs and more prescriptions to be reimbursed. At the prescriber level, there may have been an increase in the diagnosis of acid-peptic disorders, off label use, and reluctance to stop medications once started. Direct-to-consumer drug advertising (prohibited in Canada but available to the public via American media) may have led to increased patient demand for PPIs.

Long-term use of PPIs leads to alterations in the gut microbiome and changes to gastric mucosa, which have been associated with negative outcomes especially harmful to the elderly (nutritional deficiencies, bone fractures, Clostridium difficile infection, etc.). Inappropriate prescribing of PPIs may increase the use of healthcare resources through increased drug costs and treatment of adverse drug events. Evidence from Canada and other countries suggests potentially inappropriate prescribing is present in 11–70% of patients prescribed PPI therapy. The Canadian Agency for Drugs and Technologies in Health’s (CADTH) 2007 Optimal Therapy report stated that up to 31% of Canadians received a double dose as initial PPI therapy for gastroesophageal reflux disease (GERD).

One widely used tool to alert prescribers to potentially inappropriate prescribing in older adults is the screening tool of older person’s potentially inappropriate prescriptions (STOPP). With regard to PPIs, the STOPP criteria state that potentially inappropriate prescribing may be...
present if “PPI for peptic ulcer disease at full therapeutic dosage is given for greater than eight weeks,” and if this is the case, “dose reduction or earlier discontinuation is indicated.” To date, studies examining adherence to STOPP criteria for PPIs have primarily been conducted in European countries, but work is ongoing in Canada.

While the STOPP/START criteria for PPIs have not been previously implemented in Nova Scotia, other educational approaches to address potentially inappropriate prescribing have been implemented. In 2008 the Dalhousie Continuing Medical Education Academic Detailing Service sought to educate prescribers in Nova Scotia about comparative effectiveness of PPIs and Histamine-2 Receptor Antagonists (H2RAs), dosing, which patients are most likely to benefit, and adverse effects of PPIs.

The purpose of this study was to determine the concordance of PPI dispensations ‘to Nova Scotia Seniors Pharmacare (NSSP) beneficiaries with the 2008 STOPP criteria, the Dalhousie Continuing Medical Education Academic Detailing Service recommendations, and other clinical guidelines among NSSP beneficiaries. The specific objectives were to: (1) describe the use of PPIs and H2RAs 60 and 90 days after a new PPI dispensing between 1997 and 2011; (2) assess predictors of lack of adherence to adapted STOPP criteria regarding PPI use; and (3) describe PPI dispensing over time.

METHODS

Study Design and Setting
We conducted a retrospective cohort study using administrative data from Nova Scotia (population of 953,900 in 2017, with 19.8% being aged 65 and older).

Ethics
Ethics review was obtained from the Dalhousie University Health Sciences Research Ethics Board on July 24, 2013 (Reference number: 2013-3049).

Administrative Data Sources and Linkage
Data were obtained from Health Data Nova Scotia (HDNS) at Dalhousie University. The analytic dataset was created by linking four databases: the NSSP Administrative Database, the Canadian Institute for Health Information's Discharge Abstract Database, the Canadian Census Survey, and the Insured Patient Registry.

All Nova Scotians over 65 years of age without other drug coverage are eligible to receive drug insurance coverage from the NSSP program. Over 65% of eligible Nova Scotians enrolled in the program and subsequently received drug coverage through the NSSP in 2016. The NSSP database contains descriptive information about NSSP beneficiaries and is a record of the drugs dispensed and paid for by the NSSP. Centralized data on these dispensations include the age and sex of beneficiaries, as well as the anatomical therapeutic chemical (ATC; Appendix A) and type of acid suppression therapy used including dosage, duration, and dispensation date.

The Discharge Abstract Database was used to identify hospitalization at the time of cohort entry (one of the exclusion criteria). Urban/rural status of subjects was obtained from Statistics Canada and based on the forward sortation area (first three digits of the residential postal code). The Nova Scotia Medical Services Insurance (MSI) Insured Patient Registry was used to identify subjects who left Nova Scotia or died during the study period.

Study Population
We required at least 1 year of baseline data for each subject before cohort entry such that the cohort consisted of subjects ≥66 years of age between January 1, 1997 and March 31, 2011. The sample included subjects who were newly dispensed PPI therapy (i.e. who had not been dispensed any PPI therapy in the 183 days prior to cohort entry). The subjects were followed for 90 days and were censored before this if they died or left the province.
For potentially eligible subjects, the first year data were used to apply exclusion criteria to create a cohort of subjects with uncomplicated gastric disease who were targeted by the STOPP criteria. We excluded subjects with medical conditions in the year prior to cohort entry for which PPI treatment could be indicated: *Helicobacter pylori* infection, gastrointestinal bleed, Barrett’s Esophagus, Zollinger Ellison syndrome, and cancer. We also excluded subjects who were dispensed H2RAs or non-steroidal anti-inflammatory drugs (NSAIDs) in the 6 months prior to cohort entry, as this may indicate baseline gastrointestinal disease. Patients were excluded if they were hospitalized at the time of cohort entry since we do not have detailed information about medication taken during hospitalization. Refer to Appendix B for a complete list of exclusion criteria and their justifications. Refer to Appendix C for a list of the diagnostic and procedure codes used to apply these exclusion criteria.

**PPI Dosage and Duration**

Since 1992, the NSSP required specific medical indications for reimbursement of PPIs (e.g., prophylaxis of NSAID-induced complications in patients who are at high risk for gastrointestinal bleeding). PPIs were reimbursed for 12 months, after which the prescriber was required to reassess the need for continued therapy. Some generic PPIs were launched on the market in Canada in 2005, and in January 2008 the NSSP program removed the reimbursement criteria on select PPIs; therefore, these were covered as full benefits when prescribed at standard daily doses. H2RAs have never had reimbursement criteria and were covered as full benefits. For PPI therapy, we determined the prescribed daily dose using the total quantity dispensed and the listed days’ supply. We defined standard and high PPI dosages as outlined by the Dalhousie Continuing Medical Education Academic Detailing Service; these are summarized in Appendix D.55

To determine concordance with the adapted STOPP criteria, we identified subjects receiving therapy longer than 60 days after initial PPI dispensing. We followed use at 90 days after initial dispensing as this was the maximum reimbursable supply for PPIs during the study period. We examined both PPI and H2RA use at 60 and 90 days after initial PPI dispensing to account for prescriptions with a 90-day supply. At day 60 or 90, there were four possible dispensing pattern outcomes: (1) remain on PPI therapy at the same dosage category (high vs. standard), (2) remain on PPI therapy but change the dosage category (high to standard vs. standard to high), (3) switch to H2RA therapy, or (4) stop acid suppression therapy.

Dispensing patterns at day 60 were determined by the dispensing closest and up to day 60. Patients who did not have a dispensation following day 0 and up to and including day 60 were categorized as having stopped therapy. Dispensing patterns at day 90 were defined the same way as dispensing patterns at day 60. Patients who did not have a dispensing following day 0 and up to and including day 90 were categorized as having stopped therapy. We did not examine dispensing beyond 90 days.

**Adapted STOPP Criteria**

The 2008 STOPP criteria were the most recent version available to the physicians prescribing PPIs to subjects in our cohort. These guidelines state that patients with uncomplicated gastric disease should not use high-dose PPIs for longer than 60 days. This did not apply to severe GERD or peptic stricture requiring dilation or some types of severe esophagitis.23 We adapted this criterion to state that PPI therapy should not continue at any dose 60 days after being prescribed a high-dose PPI. We based this decision on several guidelines, including the Dalhousie Continuing Medical Education Academic Detailing Service document on PPIs and information from its authors, the CADTH Optimal Therapy Report...
on PPI prescribing, the Health Canada product monographs, Australian guidelines on PPI use, and the 2000 NICE guidelines. We also sought to identify subjects whose PPI therapy had not been reduced to H2RAs, which was one of the options suggested by the Dalhousie Continuing Medical Education Academic Detailing Service.

**Statistical Analyses**

All statistical analyses were conducted using SAS© software, version 9.4. Study population characteristics were summarized by frequency and proportion. The use of acid suppression therapy was described by percentage on days 60 and 90 after a new PPI dispensation.

To assess predictors of adherence to adapted STOPP criteria, only NSSP beneficiaries initially dispensed high-dose PPIs were considered. At days 60 and 90 there were two possible outcomes considered: remain on PPI therapy (at any dose) or stop PPI therapy (switch to H2RA therapy or stop all acid suppression therapy). Unadjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for each patient predictor at days 60 and 90. Multivariate logistic regression analysis was performed to assess the independent relationship between each patient predictor and outcomes at days 60 and 90. Patient predictors considered in the multivariate analysis included age, sex, urban/rural residence, and hospitalization in the year preceding cohort entry. The referent category for these analyses was stopping PPI therapy. Statistical significance was set at an alpha value of 0.05.

To describe PPI dispensing over time, the frequency of PPI dispensing was plotted over time. The proportion of high versus standard dose PPI initiation was also plotted over time.

**RESULTS**

**NSSP Beneficiaries**

A total of 14,453 subjects were included in the study cohort of NSSP beneficiaries newly dispensed PPIs, with the majority aged 66–75 years (Table 1). There were more women than men and 60% resided in urban areas. Roughly, one-third of subjects had been hospitalized in the year prior to cohort entry. The majority of subjects began PPI therapy at a standard dose (89.8%).

**PPI and other Acid Suppression Therapy Dispensing over Time**

Figure 1 summarizes acid suppression therapy dispensing patterns at day 60 compared to PPI therapy initiation. Over half (55.1%) of those beginning on standard dose PPI had stopped acid suppression therapy by day 60. A greater proportion (58.7%) of those beginning

| TABLE 1. Characteristics of NSSP Beneficiaries Newly Dispensed PPIs. |
|----------------------|------------------|------------------|
| **Patient Characteristics** | **Frequency n(%)** |
| **Age (years)** | |
| 66–75 | 8,310(57.5) |
| 76–85 | 4,468(30.9) |
| 86+ | 1,675(11.6) |
| **Sex** | |
| Female | 8,845(61.2) |
| Male | 5,608(38.8) |
| **Place** | |
| Rural | 5,822(40.3) |
| Urban | 8,631(59.7) |
| **Hospitalization in year prior to cohort entry** | |
| No | 9,147(63.3) |
| Yes | 5,306(36.7) |
| **PPI dose at cohort entry** | |
| High | 1,475(10.2) |
| Standard | 12,977(89.8) |

*Percentages may not sum to 100% due to missing values.
High/standard-dose PPI therapy defined as: Esomeprazole (40 mg once daily/20 mg once daily), Lansoprazole (30 mg twice daily/30 mg once daily), Omeprazole (40 mg once daily/20 mg once daily), Pantoprazole (40 mg twice daily/40 mg once daily), Rabeprazole (20 mg twice daily/20 mg once daily).

1 Determined based on NSSP beneficiary postal code.
on high-dose PPI had stopped acid suppression therapy by day 60 compared to those beginning on standard dose therapy. Just under half (40.9%) of subjects beginning on standard-dose PPI remained on standard-dose PPI at day 60, whereas roughly one quarter (26.4%) of those beginning on high-dose PPI remained on high-dose PPI at day 60. A small proportion of subjects switched to H2RA therapy at day 60, although this was more common in those who began on high-dose PPI. Approximately 10% of those beginning on high-dose PPI switched to standard-dose PPI at day 60. Less than 2% of those beginning on standard-dose PPI switched to high-dose PPI at day 60.

Figure 2 summarizes acid suppression therapy dispensing patterns at day 90 as compared to PPI therapy initiation. Compared to dispensing patterns at day 60, fewer subjects stopped PPI therapy, more subjects stayed at their initial PPI dose, and more subjects switched to H2RA therapy. Subjects beginning on high-dose PPI switched to standard-dose PPI at day 90 (13.2%) more often than they did at day 60 (10.3%). Subjects who began on standard-dose PPI switched to high-dose PPI more often at day 90 (1.9%) than at day 60 (1.6%), although this still represented a very small proportion of those who began on standard-dose PPI.

**Predictors of Nonadherence to Adapted STOPP Criteria**

The bivariate and multivariate logistic regressions were limited to subjects who began on high-dose PPI. Of these, 36.7% remained on PPI therapy at day 60 (Figure 1), which constituted a violation of the adapted STOPP criteria. All significant associations identified in the bivariate analysis were maintained in the multivariate analysis. Compared to subjects aged between 66 and 75 years, those aged 86 years or older were significantly more likely to continue PPI therapy at day 60 (adjusted OR = 2.4, 95% confidence interval [CI] [1.6–3.4]) and at day 90 (adjusted OR = 1.9, 95% CI [1.3–2.7]). Hospitalization within the year prior to cohort entry was significantly associated with continued PPI therapy at day 60 (adjusted OR = 1.4, 95% CI [1.1–1.7]) and at day 90 (adjusted OR = 1.2, 95% CI [1.0–1.5]). Subjects with rural postal codes were significantly more likely to continue PPI therapy at day 60 (adjusted OR = 1.3, 95% CI [1.1–1.6]) but not at day 90. Male subjects were significantly more likely than female subjects to continue PPI therapy at day 90.
(adjusted OR = 1.2, 95% CI [1.0–1.6]) but not at day 60. The results of the logistic regressions are summarized in Table 2.

**PPI Dispensing over Time**

The frequency of PPI prescriptions dispensed to NSSP beneficiaries increased roughly tenfold over our observation period. The largest jump occurred between 2007 (approximately 800 PPI prescriptions dispensed) and 2008 (approximately 3,600 PPI prescriptions dispensed).

The proportions of high- versus standard-dose PPI initiation also changed between 2007 and 2008. Standard-dose PPI became proportionally more commonly dispensed, while high-dose PPI became proportionally less commonly dispensed (Figure 3).

**DISCUSSION**

In this study, we examined potentially inappropriate prescribing of PPI usage in NSSP beneficiaries. PPI therapy was initiated at high dose in 10.2% of subjects. Of these, 36.7% continued on PPI therapy beyond 60 days, which represented potentially inappropriate prescribing according to our adapted STOPP criteria. Statistically significant predictors of potentially inappropriate prescribing after PPI initiation were age ≥86 years, hospitalization within 1 year prior to cohort entry, and rural residence.

The frequency of PPI dispensing to NSSP beneficiaries quadrupled between 2007 and 2008, with a proportional decrease in PPI initiation at high dosage. These changes coincided with the January 2008 removal of NSSP reimbursement criteria for two PPIs (rabeprazole and omeprazole). It was beyond the scope of this study to explore this further, but other factors may have influenced PPI dispensing over time. The changes in PPI dosing patterns seen in Figure 3 could be due to the Dalhousie Continuing Medical Education Academic Detailing Service or due to

| TABLE 2. Bivariate and Multivariate Associations between Patients Characteristics and PPI Dispensing at 60 and 90 days after High-Dose PPI Dispensing |
|---------------------------------------------------------------|
| **Age (years)**                                               | **Bivariate [OR (95% CI)]** | **Multivariate [OR (95% CI)]** |
|                                                              | 60 days | 90 days | 60 days | 90 days |
| 66–75                                                        | 1       | 1       | 1       | 1       |
| 76–85                                                        | 1.2 (0.9–1.5) | 1.2 (0.9–1.5) | 1.2 (0.9–1.5) | 1.2 (0.9–1.4) |
| 86+                                                          | 2.3 (1.6–3.2)* | 1.8 (1.3–2.5)* | 2.4 (1.6–3.4)* | 1.9 (1.3–2.7)* |
| **Sex**                                                      |         |         |         |         |
| Female                                                       | 1       | 1       | 1       | 1       |
| Male                                                         | 1.1 (0.9–1.4) | 1.2 (1.0–1.5)* | 1.2 (0.9–1.4) | 1.2 (1.0–1.6)* |
| **Place**                                                    |         |         |         |         |
| Urban                                                        | 1       | 1       | 1       | 1       |
| Rural                                                        | 1.3 (1.1–1.6)* | 1.1 (0.9–1.4) | 1.3 (1.1–1.6)* | 1.1 (0.9–1.3) |
| **Hospitalization 1 Year Prior to Cohort Entry**             |         |         |         |         |
| No                                                           | 1       | 1       | 1       | 1       |
| Yes                                                          | 1.4 (1.1–1.7)* | 1.2 (1.0–1.5)* | 1.4 (1.1–1.7)* | 1.2 (1.0–1.5)* |

*Statistical significance at α ≤ 0.05.
the increasing published literature related to the adverse effects of PPIs.

Our study showed a lower rate of high-dose PPI therapy initiation than the national rate reported by CADTH in 2007 (31%). Our study showed more NSSP beneficiaries remaining on PPI therapy beyond 60 days (42.5% of those initiated at standard dose, 36.7% of those initiated at high dose) compared to similar studies of Northern Ireland populations (27.9–38.9%).

Previous literature using the STOPP criteria has yielded conflicting results on the relationship between older age and potentially inappropriate prescribing of PPIs. Hospitalization has not been commonly studied as a predictor of potentially inappropriate prescribing of PPIs; however, a Canadian study at the Vancouver General Hospital found that 36% of inpatients were ordered a proton pump inhibitor without an appropriate indication. The association between hospitalization and PPI therapy seen in this population could be related to comorbidity leading to polypharmacy, which has been found to be predictive of potentially inappropriate prescribing of PPIs in multiple studies. The effect of rural residency on PPI use has not been commonly studied. The relationship seen in this study could be explained by the scarcity of rural doctors in Nova Scotia and the long distances travelled by rural residents to see their doctor. This may motivate physicians to decrease the visit burden by giving the maximum supply reimbursable by NSSP (90 days).

This was the first time adherence to STOPP criteria for PPI was explored in Nova Scotia using a large population database. Our study shows there could be a role for further guidance on PPI dose and duration. Specifically, efforts should be focused toward patients aged 86 years and older, those recently hospitalized, and those residing in rural areas. Given the large proportion of Nova Scotians on a publicly funded drug plan being dispensed PPIs, implementation of the adapted STOPP criteria represents an opportunity for decreased patient harm and wise use of public resources. A cost utility analysis by Moriarty et al. (2019) revealed interventions to deprescribe PPIs would be cost-effective when weighed against adverse effects (hip fracture and C. difficile infection) of maximal dose PPI use beyond 8 weeks. This is congruent with the position of Choosing Wisely Canada, which advises patients and doctors to avoid long-term PPI therapy without an attempt to stop/reduce PPI at least once yearly. Application of the STOPP criteria for PPIs could be facilitated through electronic health...
record and administrative data assessment to provide feedback to physicians and healthcare organizations.61–63

There were several advantages of this study. The use of longitudinal administrative data allowed for a large population-based sample that captured the majority of PPI use in our cohort.64 Our population included urban and rural older adults residing in nursing homes as well as community dwellings. Our exclusion criteria made the STOPP criteria more directly applicable to our cohort as we excluded those requiring long-term acid suppression therapy by excluding PPI use up to 1 year prior to cohort entry. In addition, we describe the context related to educational and policy initiatives that occurred in Nova Scotia, which may have impacted prescription patterns.

This study was not without limitations. Our data are older and may not reflect current prescribing practices. In Canada, omeprazole 20 mg (and salts) became available without a prescription from September 17, 2014 and esomeprazole 20 mg (and salts) became available without a prescription from August 18, 2016.64–66 Other PPIs still require a prescription in Canada. The data were collected prior to these changes and therefore may capture a greater proportion of PPI use than data collected after these PPIs became available without a prescription. Our data provide a baseline for future educational interventions and benchmark for other jurisdictions.

Our sample was limited to NSSP beneficiaries, which constituted just over 65% of Nova Scotians in this age cohort, the remainder of which may have different PPI use patterns.51 The dataset measured dispensing only; therefore, there was no information on prescribing by healthcare professionals or usage by patients. Nor were we able to determine indication for therapy or severity of symptoms on therapy initiation. We could not determine all concurrent drug therapy or concomitant diseases.

Our exclusion criteria did not eliminate all potential long-term users of PPI therapy, such as patients with erosive gastritis, esophageal strictures/dilations/varices, patients on anticoagulants, and patients receiving palliative care. We did not identify if patients began PPI therapy in hospital and these patients may have more complex indications for PPI use. We suspect that the proportion of PPI therapy initiations occurring in hospital is small and therefore the impact of excluding these patients is likely small. This is supported by a previous study examining medication adherence in patients with another common illness (diabetes), which revealed that the majority of seniors initiating medications for diabetes were not hospitalized.67 This study looked at only basic predictors of PPI usage and did not adjust for the potential confounding bias in smoking status, diet or lifestyle factors, prescriber characteristics, chronic comorbid diseases, total number of medications per patient, use of those H2RAs obtained without a prescription, or ulcer causing drugs (e.g., corticosteroids). The Charlson Comorbidity Index could not be applied to this study due to these data being unavailable in our cohort.68 We were also not able to determine patient symptoms or quality of life outcomes while receiving PPIs or on discontinuation of PPI therapy. We did not have information on prescriber characteristics such as university for medical education, years in practice, professional development activities, or practice characteristics such as solo versus group practice, etc.

In conclusion, we used population-based data to explore PPI usage in NSSP beneficiaries. There was an overall increase in PPI dispensations in this population during the study period. The majority of NSSP beneficiaries beginning PPI therapy did so on a standard initial dose, but many NSSP beneficiaries remained on PPI therapy longer than 60 days. These patients may benefit from dose reduction or limiting PPI use to on-demand therapy.69 The factors age ≥86, rural residency, and
hospitalization within the year prior to cohort entry were identified as predictors of potentially inappropriate prescribing after PPI initiation at high dosage. Through this study, we raise awareness for the STOPP criteria (developed in Europe for an international audience) and show clinicians how we and others have used the criteria to document areas of improvement for patient care.

Future research could seek to explore more predictors for potentially inappropriate prescribing of PPIs and use both qualitative and quantitative research methods to determine reasons for lack of adherence to the guidelines at the patient, prescriber, and health system levels. Future research could also examine the effects of the removal of the NSSP reimbursement criteria for rabeprazole and omeprazole over time using time series analysis. Investigation of the effects of over-the-counter PPI use on dispensations of prescribed PPIs to patients in Canada may be beneficial. The implications of increased prescribing of PPIs seen in this study could be further examined with regard to the incidence of PPI-associated health risks over time. Moreover, designing and evaluating potential interventions such as incorporating PPI STOPP criteria into computerized health record decision-making could improve adherence to the STOPP criteria.

ACKNOWLEDGMENTS AND FUNDING

The data used in this report were made available by Health Data Nova Scotia of Dalhousie University. Although this research is based on data obtained from the Nova Scotia Department of Health and Wellness, the observations and opinions expressed are those of the authors and do not represent those of either Health Data Nova Scotia or the Department of Health and Wellness. Funding was provided by the Nova Scotia Health Research Foundation (grant number: PSO-SSG-2011-7596). Resources and support for this study were also provided through the Canadian Network for Observational Drug Effect Studies.

CONFLICTS OF INTEREST

The authors have no financial or other affiliations that would represent a conflict of interest regarding this study.

REFERENCES

1. Canadian Institute for Health Information. Prescribed drug spending in Canada, 2016: A focus on public drug programs. Ottawa, ON; 2016. [cited 2019 December 20]. Available from: https://secure.cihi.ca/free_products/PrescribedDrugSpendinginCanada_2016_EN_web.pdf
2. Cammarota S, Bruzzese D, Sarnelli G, et al. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42(10):1068–78. doi: 10.1111/j.1365-2362.2012.02696.x
3. Canadian Institute for Health Information. Health care in Canada, 2011: A focus on seniors and aging. 2011. [cited 2019 December 20]. Available from: https://secure.cihi.ca/free_products/HClC_2011_seniors_report_en.pdf
4. Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada, 2012. 2012. [cited 2019 December 20]. Available from: https://secure.cihi.ca/free_products/Drug_Use_in_Seniors_on_Public_Drug_Programs_EN_web_Oct.pdf
5. Canadian Institute for Health Information. Drug use among seniors in Canada, 2016. [cited 2019 December 20]. Available from: https://www.cihi.ca/sites/default/files/document/drug-use-among-seniors-2016-en-web.pdf
6. Friedenberg FK, Hanlon A, Vanar V, et al. Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey. Dig Dis Sci. 2010;55(7):1911–7. doi: 10.1007/s10620-009-1004-0
7. Kim K-M, Cho YK, Bae SJ, et al. Prevalence of gastroesophageal reflux disease in Korea and
associated health-care utilization: A national population-based study. J Gastroenterol Hepatol. 2012;27(4):741–5. doi: 10.1111/j.1440-1746.2011.06921.x
8. Gibson S. Regulating direct-to-consumer advertising of prescription drugs in the digital age. Laws. 2014;3(3):410–38. doi: 10.3390/laws3030410
9. Aronson JK. Inhibiting the proton pump: Mechanisms, benefits, harms, and questions. BMC Med. 2016;14(1):172. doi: 10.1186/s12916-016-0724-1
10. Eusebi LH, Rabitti S, Artesiani ML, et al. Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol. 2017;32(7):1295–302. doi: 10.1111/jgh.13737
11. Schnoll-Sussman F, Katz PO. Clinical implications of emerging data on the safety of proton pump inhibitors. Curr Treat Options Gastroenterol. 2017;15(1):1–9. doi: 10.1007/s11938-017-0115-5
12. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34(4):771–85. doi: 10.1016/j.cll.2014.08.008
13. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(10):1019–24. doi: 10.1002/pds.1969
14. Haastrup PF, Rasmussen S, Hansen JM, Christensen RD, Sondergaard J, Jarbol DE. General practice variation when initiating long-term prescribing of proton pump inhibitors: A nationwide cohort study. BMC Fam Pract. 2016;17:57. doi: 10.1186/s12875-016-0460-9
15. Moriarty F, Bennett K, Cahir C, Fahey T. Characterizing potentially inappropriate prescribing of proton pump inhibitors in older people in primary care in Ireland from 1997 to 2012. J Am Geriatr Soc. 2016;64(12):e291–6. doi: 10.1111/jgs.14528
16. Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol. 2015;6:e89. doi: 10.1038/ctg.2015.20
17. Laine L, Nagar A. Long-term PPI use: Balancing potential harms and documented benefits. Am J Gastroenterol. 2016;111(7):913–5. doi: 10.1038/ajg.2016.156
18. Heidelbaugh JJ, Metz DC, Yang Y-X. Proton pump inhibitors: Are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66(6):582–91. doi: 10.1111/j.1742-1241.2012.02921.x
19. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333–40. doi: 10.1046/j.1365-2710.2000.00312.x
20. Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710. doi: 10.1038/nrgastro.2017.117
21. Fisher L, Fisher A. Acid-suppressive therapy and risk of infections: Pros and cons. Clin Drug Investig. 2017;37(7):587–624. doi: 10.1007/s40261-017-0519-y
22. Mahieu LM, De Muynck AO, Ieven MM, De Dooy JJ, Goossens HJ, Van Reempts PJ. Risk factors for central vascular catheter-associated bloodstream infections among patients in a neonatal intensive care unit. J Hosp Infect. 2001;48(2):108–16. doi: 10.1053/jhin.2001.0984
23. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahoney D. STOPP (screening tool of older person’s prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83. doi: 10.5414/cpp46072
24. Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. June 2017;65(9):1969–74. doi: 10.1111/jgs.14956
25. Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6. doi: 10.1001/jamaneurol.2015.4791
26. Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency.
Proton pump inhibitors and STOPP criteria

Gastroenterology. 2017;152(4):821–9.e1. doi: 10.1053/j.gastro.2016.11.023

27. Lue AM, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits. World J Gastroenterol. 2016;22(48): 10477–81. doi: 10.3748/wjg.v22.i48.10477

28. Mossner J. The indications, applications, and risks of proton pump inhibitors. Dtsch Arztebl Int. 2016;113(27–28):477–83. doi: 10.3238/arztebl.2016.0477

29. Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;3: CD011194. doi: 10.1002/14651858.CD011194.pub2

30. Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases—A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. doi: 10.1186/s12916-016-0718-z

31. Moriarty F, Cahir C, Bennett K, Fahey T. Economic impact of potentially inappropriate prescribing and related adverse events in older people: A cost-utility analysis using Markov models. BMJ Open. 2019;9(1):e021832. doi: 10.1136/bmjopen-2018-021832

32. Molloy DM, Molloy A, O’Loughlin C, Falconer M, Hennessy M. Inappropriate use of proton pump inhibitors. Ir J Med Sci. 2010;179(1):73–5. doi: 10.1007/s11845-009-0426-1

33. Dries AM, Richardson P, Cavazos J, Abraham NS. Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 2009;30(6):652–61. doi: 10.1111/j.1365-2036.2009.04085.x

34. Forgaics I, Loganayagam A. Overprescribing proton pump inhibitors. Br Med J. 2008;336(7634): 2–3. doi: 10.1136/bmj.39406.449456.BE

35. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ. 1998;317(7156):452–6. doi: 10.1136/bmj.317.7156.452

36. Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ. Proton pump inhibitors: A survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59(1):31–4. doi: 10.1111/j.1742-1241.2004.00298.x

37. Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease: Scientific Report, 2007. [cited 2019 December 20]. Available from: https://www.cadth.ca/sites/default/files/compus/reports/compu_PPI_summaries_overview_final.pdf

38. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing. 2015;44(2):213–8. doi: 10.1093/ageing/afu145

39. Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: A systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72. doi: 10.1111/jcpt.12059

40. Hill-Taylor B, Walsh K, Stewart S, Hayden J, Byrne S, Sketris I. Effectiveness of the STOPP/START (screening tool of older persons’ potentially inappropriate prescriptions/screening tool to alert doctors to the right treatment) criteria: Systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41(2):158–69. doi: 10.1111/jcpt.12372

41. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: A national population study. Br J Clin Pharmacol. 2010;69(5): 543–52. doi: 10.1111/j.1365-2125.2010.03628.x

42. Wahab MSA, Nyfort-Hansen K, Kowalski SR. Inappropriate prescribing in hospitalised Australian elderly as determined by the STOPP criteria. Int J Clin Pharm. 2012;34(6):855–62. doi: 10.1007/s11096-012-9681-8

43. Bradley MC, Fahey T, Cahir C, et al. Potentially inappropriate prescribing and cost outcomes for older people: A cross-sectional study using the Northern Ireland enhanced prescribing database.
Eur J Clin Pharmacol. 2012;68(10):1425–33. doi: 10.1007/s00228-012-1249-y

44. Bradley MC, Motterlini N, Padmanabhan S, et al. Potentially inappropriate prescribing among older people in the United Kingdom. BMC Geriatr. 2014;14:72. doi: 10.1186/1471-2318-14-72

45. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: A repeated cross-sectional study. BMJ Open. 2015;5(9):e008656. doi: 10.1136/bmjopen-2015-008656

46. Bjerre LM, Halil R, Catley C, et al. Potentially inappropriate prescribing (PIP) in long-term care (LTC) patients: Validation of the 2014 STOPP-START and 2012 Beers criteria in a LTC population—A protocol for a cross-sectional comparison of clinical and health administrative data. BMJ Open. 2015;5(10):e009715. doi: 10.1136/bmjopen-2015-009715

47. Bjerre LM, Ramsay T, Cahir C, et al. Assessing potentially inappropriate prescribing (PIP) and predicting patient outcomes in Ontario’s older population: A population-based cohort study applying subsets of the STOPP/START and Beers’ criteria in large health administrative databases. BMJ Open. 2015;5(11):e010146. doi: 10.1136/bmjopen-2015-010146

48. Statistics Canada. Population by sex and age group, by province and territory (% change, both sexes). 2017. [cited 2019 December 20]. Available from: http://www.statcan.gc.ca/tabs-tables/sum-som/l01/cst01/demo31a-eng.htm

49. Health Data Nova Scotia. Data access process. [cited 2019 December 20]. Available from: https://medicine.dal.ca/departments/department-sites/community-health/research/hdns/services/data-access-guidelines.html

50. Nova Scotia Department of Health and Wellness. Seniors’ pharmacare program. [cited 2019 December 20]. Available from: http://novascotia.ca/dhw/pharmacare/seniors-pharmacare.asp

51. Medavie Blue Cross MSI Health Information Department. Medical Services Insurance Annual Statistical Tables. 2016. [cited 2019 December 20]. Available from: https://novascotia.ca/dhw/publications/annual-statistical-reports/DHW_Annual_Stat_Report_MSI_2015_16.pdf

52. Statistics Canada. Population and Dwelling Count Highlight Tables. 2006 Census. 2019. Available from: https://www12.statcan.gc.ca/census-recensement/2006/dp-pd/hlt/97-550/Indx.cfm?TPL=P3C&Page=INDEX&LANG=Eng

53. Dalhousie CME Academic Detailing Service. PPIs: Burning questions. 2008. Available from: http://cme.medicine.dal.ca/ad-resources.htm

54. National Institute for Clinical Excellence. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. 2000. Available from: https://www.nice.org.uk/page.aspx?o=TA007

55. North of England Dyspepsia Guideline Development Group. Dyspepsia: Managing dyspepsia in adults in primary care. 2004. Available from: https://www.nice.org.uk/guidance/CG17

56. NPS Medicinewise. Proton pump inhibitors (PPIs): Too much of a good thing? Clinical e-Audit. 2016. Available from: https://www.nps.org.au/cpd/activities/proton-pump-inhibitors-ppis-too-much-of-a-good-thing

57. Canadian Pharmacists Association. Health Canada Product Monograph. 2016. Available from: http://www.e-therapeutics.ca

58. Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15. doi: 10.1053/j.gastro.2017.01.031

59. Wan A, Halpape K, Talkhi SC, et al. Evaluation of prescribing appropriateness and initiatives to improve prescribing of proton pump inhibitors at Vancouver General Hospital. Can J Hosp Pharm. 2018;71(5):308–15.

60. Canadian Association of Gastroenterology. Five things physicians and patients should question. Choosing Wisely Canada. 2019. Available from: https://choosingwiselycanada.org/gastroenterology/

61. Huibers CJA, Salvevelt BTGM, de Groot DA, et al. Conversion of STOPP/START version 2 into coded algorithms for software implementation: A
Proton pump inhibitors and STOPP criteria

multidisciplinary consensus procedure. Int J Med Inform. 2019;125:110–7. doi: 10.1016/j.ijmedinf.2018.12.010

62. Ivanova I, Elseviers M, Wauters M, Christiaens T, Vander Stichele R. European repository of explicit criteria of potentially inappropriate medications in old age. Geriatr Gerontol Int. 2018;18(8):1293–7. doi: 10.1111/ggi.13331

63. Black CD, Thavorn K, Coyle D, Bjerre LM. The health system costs of potentially inappropriate prescribing: A population-based, retrospective cohort study using linked health administrative databases in Ontario, Canada. Pharmacoecon Open. June 2019. doi: 10.1007/s41669-019-0143-2

64. Pendopharm. Olex (20 mg Omeprazole delayed-release tablets)—A new option for Canadians suffering from frequent heartburn. [cited 2019 December 20]. Available from: http://pendopharm.com/newsroom/olex-20mg-omeprazole-delayed-release-tablets-a-new-option-for-canadians-suffering-from-frequent-heartburn/

65. Prescription Drug Status Committee. Notice: Prescription drug list (PDL): Omeprazole. Health Canada. 2014. [cited 2019 December 20]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/omeprazole-consultation.html

66. Prescription Drug Status Committee. Notice: Prescription drug list (PDL): Esomeprazole. Health Canada. 2016. [cited 2019 December 20]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-esomeprazole.html

67. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther. 2002;27(3):213–20.

68. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82. doi: 10.1093/aje/kwq433

69. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354–64.
APPENDIX A: ATC CODES

**PPIs**
- Dexlansoprazole—A02BC06
- Esomeprazole—A02BC05
- Lansoprazole—A02BC03
- Omeprazole—A02BC01
- Pantoprazole—A02BC02 *Not classified as magnesium or sodium
- Rabeprazole—A02BC04

**H2RAs**
- Cimetidine—A02BA01
- Famotidine—A02BA03
- Nizatidine—A02BA04
- Ranitidine—A02BA02
- Ranitidine bismuth citrate—A02BA07

**NSAID**
- Indomethacin—S01BC01
- Oxyphenbutazone—S01BC02
- Diclofenac—S01BC03
- Flurbiprofen—S01BC04
- Ketorolac—S01BC05
- Piroxicam—S01BC06
- Bendazac—S01BC07
- Salicylic acid—S01BC08
- Pranoprofen—S01BC09
- Nepafenac—S01BC10
- Bromfenac—S01B

APPENDIX B: EXCLUSION CRITERIA

- Age < 66 years at cohort entry (minimum age available including one full year for baseline information).
- Prescribed an oral nonsteroidal anti-inflammatory drug (NSAID) 6 months prior to cohort entry date (patients receiving NSAIDs may require long-term proton pump inhibitor [PPI] use and are therefore not applicable to the objectives of this study).
- Patients suffering from Barrett’s Esophagus or Zollinger Ellison Syndrome (these patients may require long-term PPI use).
- Patients prescribed combination PPI and antibiotic therapy, such as PPI/Amoxicillin/Clarithromycin (PAC) (ATC code A02BD04) (these patients are treated for *Helicobacter pylori* and therefore standard clinical practice guidelines for PPI dose and duration do not apply).
- Less than 365 days of continuous observation prior to cohort entry (needed for baseline observation).
• PPI prescription within the 183 days prior to cohort entry (maximum prescription is 90 days, so 183 days of no PPI use ensures that NSSP beneficiaries are not regular PPI users).
• H2RA prescription within 183 days prior to cohort entry.
• Prescription for both PPI and H2RA at the time of cohort entry.
• Occurrence of a gastrointestinal bleed within the last year (these patients may require long-term PPI use).
• History of cancer (other than nonmelanoma skin cancer) in the 365 days prior to cohort entry (the needs of these seriously ill patients are different from our less ill population of interest, so their PPI use may not be generalizable to our population of interest).
• Hospitalization at the time of cohort entry (since we do not have detailed information about medications taken during hospitalization)

**APPENDIX C: IDENTIFICATION OF EXCLUSION CRITERIA**

The following classifications were used to identify NSSP beneficiaries who met our exclusion criteria:

• International Classification of Diseases version nine (ICD-9)
• International Classification of Diseases version nine Clinical Modification (ICD-9-CM)
• International Classification of Diseases version ten (ICD-10)
• Canadian Classification of Health Interventions (CCI)

The following are specific exclusion criteria and the codes used to identify them:

• Gastrointestinal bleed
  ° ICD 9: 531-534
  ° ICD 9-CM: 53100-53491
• History of cancer (other than nonmelanoma skin cancer)
  ° ICD 9-CM: 140-172, 174-209
  ° ICD 10: C00-C43, C45-C96
  ° Barrett’s Esophagus
    ° ICD 9: 530.85
    ° ICD-9-CM: 53085
    ° ICD 10: K227
  ° Zollinger Ellison Syndrome
    ° ICD 9: 251.5
    ° ICD 9-CM: 251.5
    ° ICD 10: 16.4
### APPENDIX D: DEFINITIONS OF STANDARD/HIGH DOSE PPI

**TABLE 1. Definitions of Standard/High-Dose PPI Therapy\(^5^3\)**

| Drug       | Standard Dose          | High Dose               |
|------------|------------------------|-------------------------|
| Esomeprazole | 20 mg once daily      | 40 mg over 24 hours    |
| Lansoprazole | 30 mg once daily      | 60 mg over 24 hours    |
| Omeprazole  | 20 mg once daily      | 40 mg over 24 hours    |
| Pantoprazole | 40 mg once daily      | 80 mg over 24 hours    |
| Rabeprazole | 20 mg once daily      | 40 mg over 24 hours    |